Cognition Therapeutics Files 8-K
Ticker: CGTX · Form: 8-K · Filed: Mar 26, 2024 · CIK: 1455365
| Field | Detail |
|---|---|
| Company | Cognition Therapeutics INC (CGTX) |
| Form Type | 8-K |
| Filed Date | Mar 26, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-reporting
TL;DR
Cognition Therapeutics filed an 8-K on 3/26/24 for financial reporting.
AI Summary
Cognition Therapeutics, Inc. filed an 8-K on March 26, 2024, reporting on its results of operations and financial condition, and including financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.
Why It Matters
This filing signifies a formal update from Cognition Therapeutics to the SEC regarding its financial status and operational results, which is important for investors to monitor.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not contain new material information that would inherently increase risk.
Key Players & Entities
- Cognition Therapeutics, Inc. (company) — Registrant
- March 26, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 2500 Westchester Avenue Purchase, NY 10577 (address) — Principal Executive Offices
FAQ
What specific financial results are being reported in this 8-K filing?
The provided text of the 8-K filing does not contain specific financial figures or details of the results of operations.
What is the primary purpose of this 8-K filing for Cognition Therapeutics?
The primary purpose is to report on the company's Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.
When was this 8-K report filed with the SEC?
This 8-K report was filed on March 26, 2024.
What is Cognition Therapeutics, Inc.'s state of incorporation?
Cognition Therapeutics, Inc. is incorporated in Delaware.
Where are Cognition Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 2500 Westchester Avenue Purchase, NY 10577.
Filing Stats: 524 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-03-26 07:12:33
Key Financial Figures
- $0.001 — h Registered Common Stock, par value $0.001 per share CGTX The Nasdaq Stock Mar
Filing Documents
- tm249736d1_8k.htm (8-K) — 26KB
- tm249736d1_ex99-1.htm (EX-99.1) — 47KB
- tm249736d1_ex99-1img01.jpg (GRAPHIC) — 12KB
- 0001104659-24-038686.txt ( ) — 269KB
- cgtx-20240326.xsd (EX-101.SCH) — 3KB
- cgtx-20240326_lab.xml (EX-101.LAB) — 33KB
- cgtx-20240326_pre.xml (EX-101.PRE) — 22KB
- tm249736d1_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition. On March 26, 2024, Cognition Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the year ended December 31, 2023. A copy of the Company's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information disclosed under Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The following exhibits are being furnished herewith: Exhibit No. Document 99.1 Press Release, dated March 26, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. COGNITION THERAPEUTICS, INC. By: /s/ Lisa Ricciardi Name: Lisa Ricciardi Title: President and Chief Executive Officer Date: March 26, 2024